



# Bio-Works Technologies AB publishes Business Update ahead of next value creation phase

Bio-Works Technologies AB (“Bio-Works” or the “Company”) hereby publishes an operational and financial update in connection with a meeting with investors conducted by the Company’s management and Board of Directors on Friday, March 6.

The information is such that Bio-Works is obliged to disclose pursuant to the EU Market Abuse Regulation (MAR).

The Company reports continued progress in line with its previously communicated strategy, with improved financial performance, strengthened commercial activity, and a fully funded plan through to break-even.

## Commercial Development

A key element of Bio-Works’ future commercial development is strengthening its position within rapidly growing biological applications such as purification of peptides, oligonucleotides, and monoclonal antibodies. The Company’s products are currently used in around **one hundred drug development projects** and **more than 20 commercial manufacturing programs** globally.

Bio-Works has identified five major commercial opportunities in Europe, North America, and Asia. China continues to represent an important and rapidly growing market. The Company estimates a potential contribution of **SEK 250–500 million** over the next 3–5 years from its core applications, depending on the continued progress of customer projects.

## Lone Carlbom, CEO of Bio-Works Technologies AB, comments:

*“Over the past year, we have executed our plan in a disciplined manner and delivered clear improvements in commercial development, margins, and operational efficiency. We are now seeing stable growth across several applications and geographies, including a number of larger opportunities that could have a significant impact on our revenue base in the medium term. With expanded capacity in place and a fully funded path to break-even, Bio-Works is well positioned for the next phase. Our focus remains on supporting our customers’ projects with high and reliable delivery quality as they advance toward clinical and commercial production.”*

## Market Conditions

According to the Company’s assessment and publicly available market data, the global biopharmaceutical market is expected to grow between **7–13 percent annually**. The chromatography resin market, currently estimated at **USD 2.5–3.3 billion**, is growing at approximately **14–19 percent** per year, with projections reaching **USD 4–5 billion** by 2030.

This growth is driven by increased production of advanced biological medicines and stricter regulatory requirements for purification processes — areas where the Bio-Works WorkBeads™ platform offers technical advantages.

## Production Capacity

During 2025, Bio-Works increased its production capacity by approximately **80 percent**, enabling annual sales levels of around SEK 150 million. The Company is currently evaluating a further doubling of capacity to approximately **SEK 300 million**, which is expected to be achievable without significant investments.

## Operational and Financial Development

Bio-Works reports that sales developed positively during 2025, and that the full-year gross margin improved to **77 percent**. Operating expenses, including personnel costs, were in line with the Company's current cost plan.

Cash and cash equivalents amounted to **SEK 34.9 million** at the end of 2025, and the order book with a total value of **SEK 32.5 million**.

Based on current planning and available liquidity, Bio-Works assesses that the business is **fully financed until break-even**.

## Outlook

Bio-Works believes the Company is entering a value creation phase, characterized by participation in fast-growing biological markets, a validated and differentiated technology platform, increasing recurring revenues, and scalable production capabilities. The Company reiterates its previously communicated goal of reaching break-even during 2027.

## Contacts:

For more information, please visit the Bio-Works homepage at [www.bio-works.com](http://www.bio-works.com) or contact: Lone Carlbom, CEO, e-mail: [lone.carlbom@bio-works.com](mailto:lone.carlbom@bio-works.com), phone: +46(0)8-502 705 84.

## About Bio-Works

Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works' headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit [www.bio-works.com](http://www.bio-works.com).

This disclosure contains information that Bio-Works Technologies AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 06-03-2026 14:00 CET.